Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on the acute local phase of herpes simplex virus-induced skin infections in mice and the establishment of latency - PubMed (original) (raw)

Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on the acute local phase of herpes simplex virus-induced skin infections in mice and the establishment of latency

R J Klein et al. Antimicrob Agents Chemother. 1985 May.

Abstract

The effect of topical and systemic treatment with 9-(1,3-dihydroxy-2-propoxymethyl)guanine on the evolution of herpes simplex virus-induced skin infection in hairless mice was investigated. Systemic (subcutaneous) treatment with a 10-mg/kg dose and topical applications with a 5% cream started up to 48 h after infection prevented the development of severe skin lesions and a fatal outcome. However, the establishment of latent infections was prevented only by topical treatment started at 6 h after infection. Systemic (50 mg/kg) and topical treatments started 48 h after infection reduced virus titers in the skin and ganglia and promoted rapid clearance of virus from these sites. The clearance of infectious virus from ganglia during the acute phase of infection was followed by early establishment of latency. 9-(1,3-Dihydroxy-2-propoxymethyl)guanine (0.03 microgram/ml) significantly inhibited the synthesis of infectious virus in explant cultures of latently infected ganglia, and at concentrations higher than 8 micrograms/ml no infectious virus was detectable in ganglia explant cultures.

PubMed Disclaimer

Cited by

Efficacies of gel formulations containing foscarnet, alone or combined with sodium lauryl sulfate, against establishment and reactivation of latent herpes simplex virus type 1.
Piret J, Lamontagne J, Désormeaux A, Bergeron MG. Piret J, et al. Antimicrob Agents Chemother. 2001 Apr;45(4):1030-6. doi: 10.1128/AAC.45.4.1030-1036.2001. Antimicrob Agents Chemother. 2001. PMID: 11257012 Free PMC article.
Comprehensive quantification of herpes simplex virus latency at the single-cell level.
Sawtell NM. Sawtell NM. J Virol. 1997 Jul;71(7):5423-31. doi: 10.1128/JVI.71.7.5423-5431.1997. J Virol. 1997. PMID: 9188614 Free PMC article.
Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model.
Thackray AM, Field HJ. Thackray AM, et al. Antimicrob Agents Chemother. 1996 Apr;40(4):846-51. doi: 10.1128/AAC.40.4.846. Antimicrob Agents Chemother. 1996. PMID: 8849238 Free PMC article.
Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections.
Faulds D, Heel RC. Faulds D, et al. Drugs. 1990 Apr;39(4):597-638. doi: 10.2165/00003495-199039040-00008. Drugs. 1990. PMID: 2161731 Review.

References

1. Infect Immun. 1977 Jun;16(3):842-8 - PubMed
1. Infect Immun. 1978 Apr;20(1):130-5 - PubMed
1. Antimicrob Agents Chemother. 1979 Apr;15(4):625-7 - PubMed
1. Antimicrob Agents Chemother. 1979 Sep;16(3):266-70 - PubMed
1. Antimicrob Agents Chemother. 1979 May;15(5):723-9 - PubMed

Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on the acute local phase of herpes simplex virus-induced skin infections in mice and the establishment of latency - PubMed (original) (raw)